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Cessation of immunosuppressive therapy after successful trans-
plantation: A national survey. A retrospective survey of 165
United States renal transplant units identified 48 patients who
had discontinued all immunosuppressive therapy (IT). Sixteen
had received cadaveric and 32 had received living-related grafts.
The interval from transplantation to cessation of medication was
similar in both groups and did not correlate with the outcome. Of
16 cadaveric grafts, 9 failed ("delta" serum creatinine concentra-
tion of  5 mg/dl) within a mean of 59 days; 3 patients maintained
stable renal function for 244, 395, and 425 days, respectively. Of
the 32 related grafts, 12 failed within a mean of 234 days. Of the
20 related grafts that did not fail, 5 had stable function for  1
year and 6 for  3 years after cessation of IT. Our data demon-
strate that at no point after transplantation is it prudent to stop all
IT barring serious drug toxicity. Also, in patients who stop IT
surreptitiously and in whom renal function remains normal,
reinstitution of therapy is indicated within 1 year and is advisable
as long as 3 years after cessation; those few patients who do well
without IT for > 3 years may not need further treatment.
Arrét du traitement immunosuppresseur après une trans-
plantation réussie: Evaluation nationale. Une evaluation retro-
spective conduite dans 165 centres de transplantation aux Etats
Unis a découvert que 48 malades ont arrété tout traitement im-
munosuppresseur (IT). Seize avaient recu des reins de cadavres
et 32 des reins de donneurs vivants apparentés. L'intervalle
entre Ia transplantation et l'arrét du traitement a été semblable
dans les deux groupes et n'a pas été corrélé a l'évolution. Parini
les 16 reins de cadavres, 9 sont devenus insuffisants ("delta" de
créatininémie  5 mgldl) au terme moyen de 59jours; 3 malades
ont eu une fonction rénale stable pendant 244, 395, et 425 jours,
respectivement. Parmi les 32 reins de donneurs vivants, 12 sont
devenus insuffisants aprés un délai moyen de 234 jours. Des 20
reins de donneurs, 5 apparentés qui n'ont pas subi d'insuffisance
rénale avaient une fonction stable après des délais  1 an et  3
ans. Nos résultats montrent qu'il n'est pas prudent, après une
transplantation, d'arréter tout traitement IT, excepté en cas de
toxicité médicamenteuse importante. Dc plus, chez les malades
qui ont arrétd le traitement clandestinement et chez lesquels Ia
fonction rénale est normale, la reprise de traitement est indiquée
au cours de Ia premiere année et souhaitablejusqu'à 3 ans après
l'arrét. 11 est possible que les malades qui vont bien sans IT de-
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puis plus de 3 ans n'aient pas hesoin dune reprise de Ia thérapeu-
tique.
Immunosuppressive therapy with prednisone and
azathioprine has been used routinely to attenuate
transplant rejection in virtually all human renal allo-
grafts for the past two decades. Despite the numer-
ous complications associated with chronic immuno-
suppressive therapy, it is generally believed that
these agents must be continued indefinitely to in-
sure graft survival. Recently, one of our patients
who had received an HLA-identical transplant
stopped all medications 3 years following surgery.
We first learned of this lapse in therapy 7 months
later; at that time renal function was still normal. In
an effort to determine whether reinstitution of im-
munosuppressive therapy is required in such pa-
tients to insure continued stability of renal function,
we surveyed all United States transplant centers for
similar cases.
Methods
A one-page questionnaire was designed request-
ing the following information: sex, age, original re-
nal disease, prior transfusions, date of transplant,
number and type of transplant, donor and recipient
blood and HLA typing, results of mixed lympho-
cyte cultures, use of antithymocyte globulin or local
graft irradiation, specifics of immunosuppressive
therapy 60 days following surgery and at the time of
cessation of medications, serum creatinine prior to
cessation (baseline) and again at either(I) the end of
the period without immunosuppressive therapy pri-
or to its reinstitution or (2) the end of the observa-
tion period without drugs; the reason for discontin-
uation of medication (medical or patient decision),
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and finally, the total number of transplants per-
formed in the center.
Questionnaires were sent to the transplant units
listed in the DHEW 1977 Directory of Medicare Ap-
proved ESRD Suppliers and to the United States
Veterans Administration Hospitals' transplant units
(total, 165).
Patients were included in the study population
only if(1) the serum creatinine was available before
and at the end of the period without immuno-
suppression; (2) all immunosuppressive medica-
tions were stopped for at least 5 days; and (3) the
donor and recipient were not identical twins. Sev-
enty-one centers responded, 28 of which provided
the 48 patients that met all criteria. These 48 pa-
tients were drawn from a total transplant population
of over 6000.
Renal failure was defined as a rise in serum creati-
nine concentration of 5 mg/dl or greater. Statistical
analyses were performed by unpaired Student's t
tests, Wilcoxon-Rank sum tests, and linear regres-
sion [1].
Results
Forty-eight patients met all criteria. There were
33 males and 15 females ranging in age from 16 to 57
years (mean age, 28 years). The patients had been
transplanted between July of 1963 and August of
1977. They were divided for analysis into three
groups: (1) living-related HLA-identical, 18 patients;
(2) living-related non-HLA-identical, 14 patients (12
nonidentical and 2 HLA-typing unspecified); and (3)
cadaveric transplants, 16 patients.
Sixty days following transplantation, most pa-
tients were receiving 20 to 60 mg/day of prednisone
(or its equivalent) and 75 to 175 mg/day of azathio-
prune. Therapy immediately prior to its discontin-
uation was similar in all groups, with most patients
receiving 10 to 30 mg/day of prednisone and 75 to
175 mg/day of azathioprine. Baseline serum creati-
nine concentrations in the HLA-identical group
ranged from 0.9 to 4.2 mg/dI, with 14 of the patients
having concentrations of 1.5 mg/dl or below. Serum
creatinine in the living related donor group ranged
from 1.2 to 2.1 mg/dl, and in the cadaveric group it
ranged from 1.0 to 2.3 mg/dl. Forty-five patients
stopped their medication on their own. Three pa-
tients discontinued therapy on their physician's ad-
vice.
As noted above, the patients were divided into
three main groups for analysis: living-related HLA-
identical (group 1); living-related non-HLA-identi-
cal (group 2); and cadaveric (group 3). For addition-
al comparative purposes, the first two groups were
combined into an "all-related donor group" (group
4). Summary data for each group and for all the pa-
tients combined (group 5) are included in Table 1.
The interval from transplantation until immuno-
suppressive medications were stopped was termed
the "immunosuppression phase"; the interval from
stopping medication until either the medications
were restarted or the most recent observations (in
cases in which immunosuppressive therapy was not
reinstituted) was termed the "no-immuno-
suppression phase."
Analysis of the data summarized in Table 1 re-
vealed no significant differences in terms of age,
sex, or the length of the immunosuppression phase
between any two groups or between any group and
the overall population. The no-immunosuppression
phase for the cadaveric group (104 139 days) was
significantly shorter than was that for the HLA-
identical group (620 790 days, P <0.02), the non-
HLA-identical group (439 702 days; P < 0.05),
and the all-related donor group (541 749 days;
P < 0.005).
Change in renalfunction after cessation of thera-
py. Of the 48 patients who stopped immunosuppres-
Table 1. Summary dataa
Group N
Age
years
Immunosuppression
phase
days
No-immunosuppression
phase
days
Graft failure
(AScr  5 mg/dl)
1. HLA-identical 18 29 1133 620 6
2. Living-related nonidentical 14 24 1015 439 6
3. Cadaveric 16 30 712 104
1 and 2) 32 27 1081 541 12
5. All patients 48 28 958 394 21
a Values are the means SD.
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sive therapy, 19 had an increase in serum creatinine
concentration of no greater than 1 mg!dl (9/18 iden-
tical, 5/14 living related, and 5/16 cadaveric). Of the
16 cadaveric grafts, 9 failed (increase in serum
creatinine of 5 rng/dl or greater) within a mean of 59
days. Of the remaining 7 patients, 4 had immuno-
suppressive therapy restarted within 1.5 months;
the 3 others have maintained stable renal function
(increment in serum creatinine of 0.8 mg!dl or less
for only 244, 395, and 425 days, respectively). Of
the 32 related grafts, 12 failed within a mean of 234
days; in 4 of these patients, clinical uremia did not
appear for 350, 425, 640, and 912 days, respectively.
There was no correlation between the immuno-
suppression phase and the subsequent level of renal
function in the patient group as a whole. Analysis of
individual groups also failed to show any significant
correlation.
Of the 20 related grafts that did not fail after dis-
continuation of immunosuppressive therapy, 5 have
had stable function for 1 to 3 years of observation.
Six additional patients have continued for 3 or more
years with no evidence of graft failure; relevant in-
formation regarding these patients is summarized in
Table 2. The first patient listed in this Table is the
individual alluded to in the Introduction.
Discussion
This study was designed to answer two major
questions (1) at what interval, if any, is it safe to
discontinue immunosuppressive therapy following
successful transplantation; (2) should therapy be
reinstituted in patients with normal renal function
who have stopped immunosuppressive therapy on
their own.
The results of any retrospective, multi-institu-
tional survey, such as the one reported here, must
be interpreted cautiously because of the potential
for biased patient selection and for nonuniform data
collection. Nevertheless, the present nationwide
survey did identify 48 patients who had stopped
therapy from a total transplant population of well
over 6000. The experience reported in these pa-
tients appears to provide an answer to the first ques-
tion, namely, that it is never entirely safe to discon-
tinue all immunosuppressive medications in renal
transplant recipients. Of the 48 patients identified,
21 experienced graft failure (serum creatinine rising
at least 5 mg/dl) before the lapse in therapy was dis-
covered, and only 6 did well for a prolonged period
( to 3 years) without reinstitution of immuno-
suppressive drugs. These results are consistent with
studies of transplantation in animals and with isolat-
ed case reports of graft failure in humans following
cessation of therapy [2—8J.
The answer to the second question, namely,
whether to restart therapy in a patient who had
stopped immunosuppressive therapy but who had
maintained adequate graft function, appears to de-
pend in part on the type of renal transplant the pa-
tient had received. In the case of cadaveric trans-
plant recipients, 9 of 16 grafts failed within a few
months, and only a few patients maintained well-
functioning grafts for more than 1 year; not a single
patient with a cadaveric graft was identified who
maintained stable renal function for longer than 2
years without immunosuppressive therapy. These
observations lead us to conclude that all patients
with cadaveric grafts and stable renal function re-
quire reinstitution of therapy no matter how long
they have been without immunosuppression.
Table 2. Long-term survivors
Immuno- No-immuno-
suppression suppression
Age Blood group HLA Type phase phase Baseline Scr Scr
Patient yr Sex (donor/recipient) (donor/recipient) days days rng/dl mg/dl
1 28 F 0/A A19A11 A19A1,
A81V22 A,\v22
1065 1425 0.9 0.0
2 26 M 0/A A2A9 A2A9
TE5( TE50
730 1800 1.0 0.3
3 27 F A/A A1A3 A1A
B7B8 B7B,
670 2920 1.1 0.1
4 32 F A/A "A-match"
sibling
868 1095 1.0 —0.1
5 26 M ?/? Sibling 30 2555 1.7 0.0
6 21 M AlA 1,8 1,8
— 15,26
1640 1370 1.2 0.5
Mean 26.7 833.8 1860.8 0.1
SD ±3.6 ±526.9 ±724.5 ±0.2
S(2)
By contrast, the present data suggest that some
patients with living-related grafts, namely, those
who have tolerated a long lapse in immunosuppres-
sion, may not require reinstitution of therapy. To
substantiate this conclusion, it is necessary to dem-
onstrate that the risk of future graft failure is accept-
ably low at some time following cessation of immu-
nosuppression in patients with living-related grafts.
Because our survey identified a number of living-
related recipients who did well for various intervals
without treatment, the data could be used to esti-
mate the risk of future graft failure following any
given "no-immunosuppression" period. For a hy-
pothetical patient who stopped medication at some
Table 3. Future risk calculation for all-related donor group
No-immuno-
suppression
phase
days
Graft
failure
No graft
failure
Future
risk
6 12 19 0.39
7 12 18 0.40
15 11 18 0.38
20 11 17 0.39
23 11 16 0.41
43 10 16 0.38
60 6 14 0.30
90 4 13 0.24
150 4 12 0.25
182 4 11 0.27
350 3 11 0.21
365 3 10 0.23
425 2 9 0.18
550 2 8 0.20
640 1 8 0.11
670 1 7 0.12
730 1 6 0.14
912 0 6 0.00
known time in the past and who still has adequate
renal function, the likelihood of future graft failure,
if treatment is not reinstituted, can be estimated as
the fraction of the present study group still at large
at that time who eventually returned for followup
with an elevated serum creatinine concentration.1 A
series of such estimates has been made for "no-im-
munosuppression" intervals from 6 to 912 days, as
depicted in Fig. 1 and Table 3. As can be seen, pa-
tients with living-related grafts who have main-
tained adequate renal function for 1 year without
therapy still have a 20% chance of eventual graft
failurt. Thus, reinstitution of treatment in such pa-
tients is clearly indicated. Even after 2 years, the
risk of graft failure is high enough (approximately
10%) to warrant restarting treatment. At some time
between 2 and 3 years, however, the risk of graft
failure appears to decline to a vanishingly low level;
none of the 6 patients who had maintained good
function without treatment for 3 years had experi-
enced graft failure up to the time of survey (0 to 825
days after the 3-year mark). Under these circum-
stances, therefore, one could argue that careful fol-
lowup (perhaps including serial self-testing for pro-
teinuria) is more prudent than reinstituting poten-
tially hazardous immunosuppressive therapy.
Unfortunately, no clinical criteria emerged from the
present data to identify which patients might do
well without immunosuppressive therapy. Review
'The denominator of this fraction does not include those pa-
tients who stopped their medications but never returned for
followup. To this extent, the denominator is an underestimate of
the number of patients actually at large, and the calculation is
thus an overestimate of the true risk.
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Fig. 1. Future risk of renal failure for the living-related donor (closed circles) group plotted as a function of the days without immuno-
suppression. The linear regression has been calculated from the data in Table 3.
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Table 4. Previously reported studies of cessation of immunosuppression
No-immunosuppression
Ref.
No. of
patients HLA typing
phase
months Outcome
[3] 2 Nonidentical 2,6 Uremic
3 Identical MLC (—) 7, 12, 30 Normal function maintained
3 Cadaver — Graft failure
[4] 3 Nonidentical
or unknown
23, 17, 8 1st 2 with normal function,
3rd with rejection at 8 months
I Identical 52 Normal function maintained
1 Cadaver 18 Rejection at 18 months,
transiently responded to medication
24 (Survey) 1— 1 '/2 (average) 14/22 patients had rejection
[5] 6 ? — 5/6 had rejection, 4/6 lost graft function
[6] 5 Living-related — All rejected except I HLA-identical who
maintained stable function at 40 months
3 Cadaver — All rejected
of the present data, as well as a review of previously
published accounts (Table 4), indicates only that the
majority of patients with long-term graft survival
are living-related HLA-identical recipients.
The pathophysiologic mechanisms responsible
for prolonged graft survival in the absence of immu-
nosuppressive therapy are unknown. In our study,
detailed immunologic testing (for example, suppres-
sor and killer cell activity, serum blocking factors)
was either not performed or not yet developed at
the time of transplantation in many of the patients
reported to us. Such information might prove useful
in deciding on the proper course of action in an indi-
vidual patient. It is interesting to speculate that
careful examination of those few patients who do
well for long periods without immunosuppression
might lead to a better understanding of the mecha-
nisms of "tolerance" in human transplantation.
Even though the present study documents the
hazards of stopping immunosuppressive therapy in
transplant recipients, solace can be taken from the
fact that so few patients do so. Less than 1% of the
large pool of patients surveyed in this report failed
to follow their prescribed immunosuppressive regi-
men; this signifies a degree of compliance probably
unsurpassed by any other patient group.
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